undamentalytics Newsletter
Sign in

Cosmos Health Inc. (COSM) stock

Add to watchlist

Add holding +

NASDAQ: COSM Nasdaq Health Care Distributors Next results ~January 25, 2027

D Fundamentals grade

Cosmos Health Inc. is a US-listed company in the health care distributors industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Cosmos Health Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling21 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds9 adding, 9 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cosmos Health files

Where Cosmos Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $74m, up 33.8% on a year earlier, faster than the 29.8% growth a quarter earlier. That growth ranks 86 of 427 among the health care companies we cover. Free-cash-flow margin fell to -13.5% from -8.8% a year earlier. The diluted share count is up 79.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 7 financial-health checks.

Our model value for Cosmos Health is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 18, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 25, 2027 (estimated)

Cosmos Health Inc.'s trailing-twelve-month revenue grew 33.8% year on year, with a free-cash-flow margin of -13.5%. Where it stands out: revenue growth of 33.8% ranks 1 of 6 health care distributors companies we cover. Where it lags: operating margin of -24.9% ranks 6 of 6 health care distributors companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 105.8% while net income fell 58.7%: a 47pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 33.8% over the last 12 months, against a median of 6.5% for health care distributors companies we cover.
  • Growth speeding up. The growth rate is 4.1 points higher than a quarter earlier.

Things to watch

  • Loss-making. Operating margin is -24.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -13.5% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 79.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 98% and a beta of 1.5 against the S&P 500.
  • Below peers: stock pay as % of revenue. Stock pay as % of revenue of 2.3% ranks 5 of 5 health care distributors companies we cover (median 0.1%).
  • Below peers: days sales outstanding. Days sales outstanding of 93 days ranks 5 of 5 health care distributors companies we cover (median 47 days).

Latest results: FY2026 Q2

Filed August 18, 2026
Earnings per share
-$0.10 against an average estimate of $0.01: missed by 1100.0%
Revenue
$19m, up 28.8% on a year earlier
Share reaction
-7.1% in the first session after the results on October 22, 2026, against -1.7% for the S&P 500
Guidance given
U.S. revenue $15m (Q4 2026); gross profit $10.5m (Q4 2026)

Cosmos Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.3%
  • 1 week+33.2%
  • 1 month-18.7%
  • This year-38.0%
  • 1 year-61.9%
  • 5 years-92.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$73.7M
Operating margin
-24.9%
Net margin
-33.1%
EPS (TTM, diluted)
$-0.56

Growth

Revenue growth
+33.8%
Change in growth rate
+4.1 pts
Share count change
+79.3%

Cash

Free cash flow (TTM)
-$9.9M
FCF margin
-13.5%
Stock pay % of revenue
2.3%

Earnings

Last results
October 22, 2026
Next results (est.)
January 25, 2027

News & updates

Updated November 1, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Results
  4. Results
  5. Leadership
  6. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cosmos Health Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Cosmos Health Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$4.3 ~$3.3–$5.4 Left out: out of range vs price (13.85x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$0.2–$0.7 Left out: out of range vs price (0.19x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cosmos Health Inc. with Health Care Distributors in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$8.00$8.20$10.20$4.00$2.20$5.10$3.37$4.56$1.41$0.67$0.50$0.31
Market value$15m$15m$20m$8m$4m$10m$7m$9m$17m$13m$15m$13m
+ Net debt (− = net cash)−$198049−$716590−$661249$9m$13m$23m$23m$5m$7m$11m$15m$10m
Enterprise value$15m$15m$19m$17m$18m$33m$30m$14m$24m$24m$30m$24m
Multiples
Price / sales 28.2x2.3x0.7x0.2x0.1x0.2x0.1x0.2x0.3x0.2x0.2x0.2x
Price / earnings —————12.4x——————
Price / free cash flow ————————————
EV / EBITDA ————128.5x10.7x——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

22 /100

Weak moat

How hard Cosmos Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -30.2% of total assets over 10 years.

  • Pricing power 7 / 20

    Gross margin has been a median 9.2%, moving by 3.1 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -12.4%; its worst year was -37.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -14.7% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 235.3% over five years; stock-based pay has been a median 1.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (27 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.15 +76% $85m +31%
Next $0.07 +147% $130m +52%

Next year's EPS estimate has moved 0.0% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1600.0% on 90 days ago. In the last 30 days, 0 analysts raised Cosmos Health Inc.'s forecast and 1 cut it.

Consensus EPS forecast Cosmos Health Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 $0.10 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.01 Current fiscal year, 60 days ago: −$0.21 Current fiscal year, 30 days ago: −$0.21 Current fiscal year, 7 days ago: −$0.22 Current fiscal year, Now: −$0.15 −$0.15 Next fiscal year, 90 days ago: $0.07 Next fiscal year, 60 days ago: $0.07 Next fiscal year, 30 days ago: $0.07 Next fiscal year, 7 days ago: $0.07 Next fiscal year, Now: $0.07 $0.07

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.01$0.07
60 days ago −$0.21$0.07
30 days ago −$0.21$0.07
7 days ago −$0.22$0.07
Now −$0.15$0.07

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.01 −$0.10 −1100.0%
Mar 2026 −$0.01 −$0.03 −186.0%
Dec 2025 −$0.04 −$0.36 −809.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 22, 2026
  • gross margin · U.S. Q4 2026 about 70%
    “Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin” source
  • U.S. revenue Q4 2026 about $15m
    “Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company's current growth trajectory” source
  • gross profit · U.S. Q4 2026 about $10.5m
    “Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin” source
  • subscription revenue Q4 2026 about $11.5m
    “Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals” source
  • first orders from new subscribers Q4 2026 about $8.2m
    “Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals” source
  • renewals of subscriptions Q4 2026 about $3.3m
    “Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals” source
Show 3 more items
  • one-time purchases fourth quarter about $3.5m
    “One-time purchases are expected to contribute the remaining approximately $3.5 million.” source
  • active U.S. subscriptions year-end about 40,000
    “Subscription growth: 8,940 active subscriptions as of October 19, 2026, up 42% from the 6,287 announced on October 14, 2026, with more than 40,000 expected by year-end” source
  • U.S. daily sales year-end about $200,000
    “As a result, the Company expects U.S. daily sales to more than triple during the quarter, from $60,000 at its start to more than $200,000 by year-end, and expects active U.S. subscriptions to exceed 40,000 by year-end, more than four times current levels.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 20260
  3. Aug 20260
  4. Jul 20260

Counts of recommendations published by analysts covering Cosmos Health Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.7%
of tradable shares
Days to cover
0.57
at average volume
Short interest, 1 month
−24%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
23.9%
of shares
Employees
163
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
COSM−34%+35%−69%−53%−26%−38%
Industry peers (median)+44%+26%+24%+10%+45%+8%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
COSM50%42%50%33%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
COSM−62%−98%−86%−66%−67%−69%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from March 5, 2018 to November 9, 2022. Getting back needed a 17023% gain, reached on December 16, 2022, 37 days after the low.

Price behaviour

52-week range
$0.17 – $0.78
From 52-week high
−60.2%
vs 50-day average
+2.5%
vs 200-day average
−0.4%
Volatility (1 year)
98%
Beta vs S&P 500
1.46

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±8.5%
After a week
7 up, 5 down
typical move ±19.4%
After a month
4 up, 6 down
typical move ±1903.2%
Results releasedNext dayS&P 500 next day5 days21 days
October 22, 2026 −7.1% −1.7% −1.1% —
October 9, 2026 +11.5% +0.5% +5.4% —
August 20, 2026 +15.0% −0.4% +11.9% +75.6%
May 22, 2026 +3.1% +1.1% −0.8% −18.4%
April 16, 2026 +3.8% +1.5% −8.7% −22.8%
November 17, 2025 −3.0% −1.8% −4.6% −30.1%
November 22, 2023 +5.8% +0.4% +1.0% +35.0%
August 15, 2023 0.0% −1.9% −3.0% −3.7%
April 18, 2023 −4.7% 0.0% +7.2% +11.6%
November 16, 2022 +7.4% −1.1% +162.3% +18760.7%
August 23, 2022 +14.3% +0.1% +7.6% −24.0%
May 18, 2022 +26.7% −4.6% +18.9% −50.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cosmos Health Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cosmos Health Inc.
$40M $50M $60M $70M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $49.6M Revenue (TTM), FY23 Q4: $53.4M Revenue (TTM), FY24 Q1: $55.6M Revenue (TTM), FY24 Q2: $56.5M Revenue (TTM), FY24 Q3: $56M Revenue (TTM), FY24 Q4: $54.4M Revenue (TTM), FY25 Q1: $53.6M Revenue (TTM), FY25 Q2: $55.1M Revenue (TTM), FY25 Q3: $59.8M Revenue (TTM), FY25 Q4: $65.3M Revenue (TTM), FY26 Q1: $69.5M Revenue (TTM), FY26 Q2: $73.7M $73.7M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $49.6M
FY23 Q4 $53.4M
FY24 Q1 $55.6M
FY24 Q2 $56.5M
FY24 Q3 $56M
FY24 Q4 $54.4M
FY25 Q1 $53.6M
FY25 Q2 $55.1M
FY25 Q3 $59.8M
FY25 Q4 $65.3M
FY26 Q1 $69.5M
FY26 Q2 $73.7M
Revenue growth, TTM YoY Cosmos Health Inc.
-20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -9.0% Revenue growth, TTM YoY, FY23 Q4: 6.0% Revenue growth, TTM YoY, FY24 Q1: 12.1% Revenue growth, TTM YoY, FY24 Q2: 15.7% Revenue growth, TTM YoY, FY24 Q3: 13.0% Revenue growth, TTM YoY, FY24 Q4: 2.0% Revenue growth, TTM YoY, FY25 Q1: -3.7% Revenue growth, TTM YoY, FY25 Q2: -2.4% Revenue growth, TTM YoY, FY25 Q3: 6.7% Revenue growth, TTM YoY, FY25 Q4: 19.9% Revenue growth, TTM YoY, FY26 Q1: 29.8% Revenue growth, TTM YoY, FY26 Q2: 33.8% 33.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -9.0%
FY23 Q4 6.0%
FY24 Q1 12.1%
FY24 Q2 15.7%
FY24 Q3 13.0%
FY24 Q4 2.0%
FY25 Q1 -3.7%
FY25 Q2 -2.4%
FY25 Q3 6.7%
FY25 Q4 19.9%
FY26 Q1 29.8%
FY26 Q2 33.8%
Operating margin (TTM) Cosmos Health Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -31.3% Operating margin (TTM), FY23 Q4: -40.9% Operating margin (TTM), FY24 Q1: -37.8% Operating margin (TTM), FY24 Q2: -37.1% Operating margin (TTM), FY24 Q3: -36.0% Operating margin (TTM), FY24 Q4: -28.6% Operating margin (TTM), FY25 Q1: -27.2% Operating margin (TTM), FY25 Q2: -26.7% Operating margin (TTM), FY25 Q3: -23.9% Operating margin (TTM), FY25 Q4: -25.6% Operating margin (TTM), FY26 Q1: -26.0% Operating margin (TTM), FY26 Q2: -24.9% -24.9%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -31.3%
FY23 Q4 -40.9%
FY24 Q1 -37.8%
FY24 Q2 -37.1%
FY24 Q3 -36.0%
FY24 Q4 -28.6%
FY25 Q1 -27.2%
FY25 Q2 -26.7%
FY25 Q3 -23.9%
FY25 Q4 -25.6%
FY26 Q1 -26.0%
FY26 Q2 -24.9%
FCF margin (TTM) Cosmos Health Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -56.9% FCF margin (TTM), FY23 Q4: -31.8% FCF margin (TTM), FY24 Q1: -25.3% FCF margin (TTM), FY24 Q2: -14.8% FCF margin (TTM), FY24 Q3: -5.9% FCF margin (TTM), FY24 Q4: -14.9% FCF margin (TTM), FY25 Q1: -9.0% FCF margin (TTM), FY25 Q2: -8.8% FCF margin (TTM), FY25 Q3: -13.1% FCF margin (TTM), FY25 Q4: -13.0% FCF margin (TTM), FY26 Q1: -13.5% FCF margin (TTM), FY26 Q2: -13.5% -13.5%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -56.9%
FY23 Q4 -31.8%
FY24 Q1 -25.3%
FY24 Q2 -14.8%
FY24 Q3 -5.9%
FY24 Q4 -14.9%
FY25 Q1 -9.0%
FY25 Q2 -8.8%
FY25 Q3 -13.1%
FY25 Q4 -13.0%
FY26 Q1 -13.5%
FY26 Q2 -13.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 8 1 7 30 37 40 55 56 50 53 54 65 74
Gross profit — 8 0 1 2 2 4 8 8 6 4 4 8 8
EBITDA — 7 −0 −0 −5 −1 0 3 −4 −7 −21 −14 −15 −17
Operating income 0 7 −0 −0 −5 −1 −0 3 −5 −7 −22 −16 −17 −18
Net income 0 6 −7 −1 −6 −9 −3 1 −8 −14 −19 −16 −19 −24
Diluted EPS $0.00 $0.33 −$0.33 $538273.33 −$3.27 −$4.53 −$1.67 $0.40 −$7.91 −$33.16 −$2.15 −$1.17 −$0.63 −$0.56
Growth (year on year)
Revenue — +746.6% −93.0% +>999% +344.3% +23.6% +7.0% +39.6% +1.5% −10.5% +6.0% +2.0% +19.9% +33.8%
EBITDA — — −106.1% — — — — — −234.4% — — — — —
Operating income — +>999% −106.2% — — — — — −267.0% — — — — —
Net income — +>999% −210.6% — — — — — — — — — — —
Diluted EPS — — −200.0% — — — — — — — — — — —
Margins
Gross margin — 100.0% 9.2% 8.9% 6.5% 6.5% 9.2% 14.5% 14.8% 11.8% 8.1% 7.9% 12.1% 10.3%
EBITDA margin — 93.3% −81.9% −2.9% −16.2% −3.2% 0.3% 5.6% −7.4% −14.6% −39.7% −26.3% −23.5% −23.0%
Operating margin 32.0% 93.2% −82.9% −3.0% −16.2% −3.3% −0.6% 4.9% −8.1% −14.8% −40.9% −28.6% −25.6% −24.9%
Net margin 27.3% 79.1% <−999% −8.9% −20.7% −24.4% −8.3% 1.5% −14.2% −27.5% −34.7% −29.7% −29.3% −33.1%
Free-cash-flow margin — 85.1% −101.4% −31.7% −29.4% −5.6% — −21.0% −13.7% −29.7% −31.8% −14.9% −13.0% −13.5%
Cash flow
Cash from operations 1 7 −0 −2 −9 −2 −5 −12 −7 −15 −16 −8 −8 −10
Capital spending — 0 0 0 0 1 — 0 1 0 1 0 0 0
Free cash flow — 7 −1 −2 −9 −2 — −12 −8 −15 −17 −8 −9 −10
Stock-based pay — — 0 0 0 0 — — 6 0 1 2 2 2
Free cash flow after stock pay — — −1 −2 −9 −2 — — −14 −15 −18 −10 −11 −12
Balance sheet
Cash 1 0 0 1 1 1 0 1 0 21 4 0 1 2
Total debt 0 0 0 0 0 10 14 24 24 26 11 11 16 12
Net debt (negative = net cash) −1 −0 −0 −1 −1 9 13 23 23 5 7 11 15 10
Diluted shares 2m 2m 2m 2m 2m 2m 2m 2m 2m 2m 12m 19m 30m 43m
Returned to shareholders
Buybacks — — — — — — — 0 0 — 0 0 — —
Total returned — — — — — — — 0 0 — 0 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $61m
Short-term assets $37mLonger-term assets $25m
What it owes, and who funded it · $61m
Short-term liabilities $35mLonger-term liabilities $6mShareholders' equity $21m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $35m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $6m of longer-dated liabilities.
  • More cash than debt $2m of cash against $3m of debt.
  • Debt below 40% of shareholders' equity Debt is 15% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 11% to 15% over five years.
  • A year's operating cash flow covers at least 20% of debt −$10m of operating cash flow against $3m of debt.
  • Operating profit covers interest at least five times over Operating income of −$18m against $2m of interest.

From Cosmos Health Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+79.3%
year over year
R&D spending
0.7%
of revenue
Days sales outstanding
93 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care distributors
Last 12 months unless stated COSM HKPD YI HSIC COR MCK Median
Revenue, last 12 months $74m $13m $1.7bn $13.6bn $332.8bn $411.0bn $7.7bn
Revenue growth, last 12 months 33.8% −33.9% −12.7% 6.5% 5.1% 8.8% 5.8%
Revenue growth, 3-year average 14.8% — — 2.6% 9.4% 13.1% 11.2%
Revenue growth, latest quarter 28.8% — — 6.7% 5.1% 7.7% 7.2%
Gross margin 10.3% 10.3% 5.8% 31.3% 4.0% 3.6% 8.0%
Operating margin −24.9% −17.8% −0.0% 5.0% 0.9% 1.6% 0.4%
Operating margin, 3-year average −29.5% — −10.6% 4.8% 0.9% 1.3% 0.9%
Net margin −33.1% −8.5% −0.5% 3.0% 0.8% 1.1% 0.1%
Cash from operations / revenue −13.3% −5.6% 0.9% 5.1% 1.4% 1.7% 1.2%
Free-cash-flow margin −13.5% −5.9% 0.9% 4.2% 1.2% 1.6% 1.1%
Free-cash-flow margin, 3-year average −12.4% — −9.0% 3.8% 1.0% 1.4% 1.0%
Stock pay / revenue 2.3% — 0.1% 0.3% 0.0% 0.1% 0.1%
Change in share count 79.3% 60.2% 1.3% −6.1% −0.5% −3.4% 0.4%

Median of all 6 companies we cover in health care distributors. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

6 health care distributors companies
Measure Company Peer median Rank
Revenue growth Growth 33.8% 6.5% 1 of 6
Change in growth rate Growth +4.1pp -0.9pp 1 of 6
Gross margin Profitability 10.3% 10.3% 3 of 6
Operating margin Profitability -24.9% 0.9% 6 of 6
Net margin Profitability -33.1% 0.8% 6 of 6
Free-cash-flow margin Cash generation -13.5% 1.2% 6 of 6
Stock pay as % of revenue Cash generation 2.3% 0.1% 5 of 5
Long-term debt as % of assets Balance sheet 5.2% 13.7% 1 of 5
Change in share count Balance sheet 79.3% 1.3% 6 of 6
Days sales outstanding Balance sheet 93 days 47 days 5 of 5

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Wholesale $59.3M 90.9% ▲ 15.0%
Nutraceuticals and Pharmaceuticals $4.3M 6.5% ▲ 116.7%
Pharmamanufacturing $1.7M 2.6% ▲ 95.2%
Other $1,228 0.0% —

From Cosmos Health Inc.'s 10-K filed April 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$389,499
Institutions reporting
18
Shares held vs prior quarter
▲ 43.1%
Positions opened / closed
3 / 5

Top buyers and sellers, Q2 2026: 9 institutions bought and 9 sold ; the biggest buyer was UBS Group AG (+582K shares) and the biggest seller Renaissance Technologies LLC (−391K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
UBS Group AG $109,975 594K 28.2% ▲ 4568.3%
Vanguard Fiduciary Trust Co $61,761 334K 15.9% ▲ 248.7%
Jane Street Group, LLC $53,431 289K 13.7% New
Geode Capital Management, LLC $52,110 282K 13.4% ▼ 11.3%
Blackrock, Inc. $49,462 268K 12.7% 0.0%
Vanguard Capital Management LLC $32,184 174K 8.3% ▲ 24.3%
Northern Trust Corp $9,953 54K 2.6% ▲ 162.2%
State Street Corp $8,356 45K 2.1% 0.0%
Sassicaia Capital Advisers LLC $6,649 36K 1.7% New
Kestra Private Wealth Services, LLC $2,401 13K 0.6% New
Simplex Trading, LLC $1,320 7K 0.3% ▲ 87.7%
National Bank Of Canada $1,144 6K 0.3% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cosmos Health Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.7M 21 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.7M net buying
Insider Date Trade Shares Price Value
Siokas Grigorios Chief Executive Officer July 30, 2026 Buy 349,825 $0.20 $69,965
Siokas Grigorios Chief Executive Officer July 29, 2026 Buy 766,284 $0.18 $137,931
Terzis Georgios Chief Financial Officer June 16, 2026 Buy 168,135 $0.25 $42,034
Siokas Grigorios Chief Executive Officer June 11, 2026 Buy 218,447 $0.21 $45,874
Siokas Grigorios Chief Executive Officer June 10, 2026 Buy 701,447 $0.23 $161,333
Siokas Grigorios Chief Executive Officer February 12, 2026 Buy 388,532 $0.37 $143,757
Siokas Grigorios Chief Executive Officer February 11, 2026 Buy 291,262 $0.41 $119,417
Siokas Grigorios Chief Executive Officer January 23, 2026 Buy 90,325 $0.50 $45,162
Siokas Grigorios Chief Executive Officer January 20, 2026 Buy 353,321 $0.50 $176,660
Siokas Grigorios Chief Executive Officer January 14, 2026 Buy 493,495 $0.45 $222,073
Siokas Grigorios Chief Executive Officer January 12, 2026 Buy 113,185 $0.50 $56,592
Siokas Grigorios Chief Executive Officer January 8, 2026 Buy 156,190 $0.52 $81,219

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 25, 2027 estimated from the company's past filing pattern, not announced

  • October 22, 2026
  • October 9, 2026
  • August 20, 2026
  • May 22, 2026
  • April 16, 2026
  • November 17, 2025

Recent SEC filings

Data status

When each part of this page on Cosmos Health Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cosmos Health Inc. in brief

What does Cosmos Health Inc. do?
Cosmos Health Inc. is a US-listed company in the health care distributors industry. Its financial year ends in December.
What is Cosmos Health Inc.'s stock ticker?
Cosmos Health Inc. trades under the ticker COSM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cosmos Health Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cosmos Health Inc. reported revenue of $73.7M, 33.8% higher than a year earlier, according to its SEC filings.
What is Cosmos Health Inc.'s free cash flow?
Cosmos Health Inc.'s free-cash-flow margin is -13.5% of revenue over the trailing twelve months, ranking 6 of the 6 health care distributors companies we cover.
Who are Cosmos Health Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are UBS Group AG, Vanguard Fiduciary Trust Co and Jane Street Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cosmos Health Inc.'s market cap?
On November 2, 2026, Cosmos Health Inc.'s market capitalisation was about $13.4M and net debt of $10.3M. Market figures come from third-party market data and may be delayed.
How much debt does Cosmos Health Inc. have?
Cosmos Health Inc.'s debt-to-equity ratio is 15.5%, from its latest balance sheet (10.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are Cosmos Health Inc.'s competitors?
In our Health Care Distributors peer group, the companies closest to Cosmos Health Inc. are Cellyan Biotechnology Co., Ltd, 111, Inc., Henry Schein, Cencora and McKesson. The side-by-side comparison below sets their revenue, margins and growth against Cosmos Health Inc.'s.
Are insiders buying or selling Cosmos Health Inc. stock?
Over the last 12 months, Cosmos Health Inc.'s directors and officers reported 21 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Cosmos Health Inc.'s next earnings date?
Around January 25, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cosmos Health Inc. announces its own schedule.